|
|
Other links at Articles > Diabetes and Endocrinology |
| 1. |
First-Line EGFR Inhibition May Benefit Selected Lung Cancer Patients
|
|
|
There is "strong evidence" that selected groups of patients with advanced non-small cell lung cancer (NSCLC) may benefit from first-line therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, according to the authors of a report in the March issue of the Journal of Thoracic Oncology. Reuters Health Information
|
| 2. |
ADA 2008: Clinical Questions
|
|
|
Is there value in the early detection of type 2 diabetes? Are there differences between rosiglitazone and pioglitazone? Medscape Diabetes & Endocrinology
|
| 4. |
Weight-Loss Drugs May Harm Developing Brain: Study
|
|
|
A drug from a new class of weight-loss treatments disrupted brain development in young mice, U.S. researchers said on Wednesday, raising concerns about using these drugs in children. Reuters Health Information
|
|
|